Thus, the collection of our data in this work, together with our recent findings [14], [15], demonstrated that the benefits of OXT in treating metabolic diseases are multi-faceted, range from obesity control to body weight-independent improvements of insulin sensitivity and insulin secretion. This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.